Roles
- Professor, Department of Psychiatry & Behavioral Sciences, Neurology
- Director, Cognitive Neurosciences and Aging (CNSA)
- Associate Director of the Florida Alzheimer’s Disease Research Center
- Director of the UM Clinical Core
-
Biography
Dr. Loewenstein Loewenstein has had continuous NIH grant funding for over 30 years. He is Principal Investigator on several large NIH and state funded grants and has a number of ongoing longitudinal investigations nationally and internationally with new cognitive instruments developed in his laboratory. The Direct Assessment of Functional status Scale (DAFS) was one of the first performance-based scales for Alzheimer’s disease and has been translated into multiple languages. The Semantic Interference Test (SIT) and the Loewenstein- Acevedo Scales for Semantic Interference and Learning (LASSI-L) have shown considerable promise in the early detection and prediction of progression in patients with early Alzheimer’s disease and other neurodegenerative disorders. Susceptibility to proactive semantic interference (PSI) and most importantly, the failure to recover from semantic interference (frPSI) are extremely sensitive markers of preclinical AD, progression over time and brain biomarkers of amyloid load, tau load, cortical thickness and brain volumetric loss. Dr. Loewenstein and colleagues have recently made discoveries in the the the areas of failures of inhibitory control and unbinding of previously learned semantic associations. Dr. Loewenstein’s directs the Center for Cognitive Neuroscience and Aging and works with many departments across the UM and numerous medical schools and Universities across the United States and abroad. -
Education & Training
Education
Licensures and Certifications
-
Teaching Interests
Dr. Loewenstein has mentored many post-doctoral fellows in neuropsychology and numerous PhD and MD residents in numerous disciplines. His laboratory is committed to training the next generation of leaders is the study of the brain, novel cognitive challenge tests, state-of- the science neuroimaging and other biomarkers to detect incipient Alzheimer's disease and related disorders. -
Research Interests
Dr. Loewenstein has a number of research interests centering on the early detection of early cognitive impairment in neurodegenerative and other brain disorders, development of novel cognitive and functional measures, examining relationships between neuropsychological measures and neuroimaging and other biomarkers of early Alzheimer’s disease. Further, Dr. Loewenstein and other investigators in his laboratory have been involved in developing cognitive and functional interventions for normal elderly patients as well as those with Alzheimer’s disease (AD) and related disorders and development of culture fair assessment instruments. -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Grants & Sponsored Research
ActiveCompleteViewing number of total completed grants
Articles & News
Blood Biomarkers and Cognitive Testing Improve Prediction of Early Alzheimer’s Decline
Miller School of Medicine Researchers Build Real‑World Model of Alzheimer’s Risk
Challenging Alzheimer’s Disease
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 1 clinical trials.